General Principles of Medicines Regulation Dr Lembit Rägo Coordinator Quality Assurance and Safety:...

General Principles of Medicines Regulation

Dr Lembit RägoCoordinator

Quality Assurance and Safety: Medicines (QSM)Medicines Policy and Standards (PSM)

WHO Headquarters, Geneva, [email protected]

Meeting on WHO Prequalification Programme on Priority Essential Medicines, WHO/EMRO

6-7 June 2007, Cairo, EGYPT

1

2

Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals

Topics

Innovative and generic medicines Product information Structure of the dossier of medicinal products

3


Usual perceptions may not help to make judgments about medicines …and even pharmacists and medical doctors may not be in capacity of taking decisions without specific training

SmellAppearance Taste

4


Why medicines are special category of products?

Consumers, patients and health care workers have limited capacity to judge there

SAFETY QUALITY EFFICACY

5


Are all medicines safe, effective and meet quality criteria?

No, they are not, and no they do not

Some are safe, but not effective or necessarily meet the quality criteria

Some may be effective, meet quality criteria but are not safe

Some meet quality criteria but are not necessarily safe or have any efficacy

6


Quality - Safety

Some safety parameters are determined by quality

Some safety parameters are determined by the intrinsic properties of active pharmaceutical ingredient

However, in fact QUALITY in general perception (and often in policy documents) is incorporating also expectations for efficacy and safety without necessarily saying so

7


What type of medicines we have?

Originator products

Multisource (generic) products

KEY – INTERCHANGEABILITY, more important THERAPEUTIC INTERCHNGEABILITY

ALL LITERATURE IS BASED ON ORGINATORS

No interchangeability – NEED FOR NEW SAFETY and EFFICACY DATA, NEW BOOKS HAVE TO BE WRITTEN

8


What type of regulations exist and how they differ?

For innovator products proof of QUALITY, SAFETY and EFFICACY is needed

For multisource products QUALITY, safety and efficacy data is referred to the originator, providing only evidence about interchangeability (bioequivalence, clinical testing, in certain cases dissolution data)

9


Generics and not generics

FDA requirements for generic drugs (www.fda.gov/cder/ogd)

Generic drugs must: 1. contain the same active ingredients as the innovator

drugs as the innovator drug2. be identical in strength, dosage form, and route of

administration3. have the same use indications 4. meet the same batch requirements for identity ,

strength, purity and quality5. be manufactured under the same strict standards of

GMP required for innovator products.6. be bio-equivalent

10


11


12


Generic drugs

In case of safety and efficacy the only way is to refer to originator product Thus the efficacy (indications, dosing) and safety information (side

effects, warnings etc.) can not be different But are they?

13


Regulations: Global vs National

National regulations still differ a lot – especially for generics

What is ICH and what it is not?

Regional harmonization initiatives

Do global norms exist for generics?

14


Who sets the standards?Is the WHO Involved?

WHO has the unique mandate to set standards

WHO Constitution (Chapter II, Article 2), inter alia, states (6): In order to achieve its objective, the

functions of the organization shall be:… to develop, establish and promote

international standards with respect to food, biological, pharmaceutical and similar products;

Example of WHO work from 1966

15


16


Mission and objectives clearly stated Possibility to assess attainment of objectives Procedures and outcomes transparent to applicants, health

professionals, and public Arguments used to reach decision accessible to the public Reasonable duration of assessment without compromising

quality, safety & efficacy Expedite review for orphan and outstanding public-health-value

drugs Accountability to government, those regulated, and the public Personnel adequately trained, highly qualified, of high integrity Human resource development programme Mechanisms for appeal and for citizens' complaints Access to appropriate knowledge and technology Citizens are provided with accurate and appropriate drug

information Mechanisms to ensure quality of operating procedures

Good Regulatory Practice : 9th ICDRA 29/4/1999

17


Intrinsic safety issues (NOT quality related)

Not a single drug is completely safe! Predictable and preventable ADRs/ADEs New, unpredictable and unpreventable ADRs

New concepts - safety through whole life cycle of a drug Preclinical testing First in man trials Clinical trials to prove efficacy (pre-marketing) Post-marketing activities for gathering new data (Phase IV trials,

prosepective pharmacovigilance planning, targeted monitoring etc) ADR reports and data analysis Constant improving of INFORMATION on medicine and

communication

18


Completely safe medicines are a myth: low dose aspirin case

Usefulness of low dose aspirin (75-325 mg) in secondary prevention of thrombotic cardiovascular or cerebrovascular disease proven

In many countries it is also approved for primary prevention of vascular events of coronary heart disease (US FDA has approved only secondary prevention).

Usefulness and efficacy is ALWAYS balanced against the risk – the higher the risks the higher risks in terms of safety we may wish to take

If NO DISEASE low dose aspirin can increase a risk to die (from hemorrhagic stroke) …

19


How big is a problem?

A recent US study estimated that 106 000 patients die and 2.2 million are injured each year by adverse reactions to prescribed drugs (Lazarou et al, 1998).

RATIONAL USE is a key to avoid ADRs that are predictable and avoidable

Important role of INFORMATION

20


21


Specific reviews of medicinesSpecific reviews of medicines

Review of Kava Pharmacovigilance for

antiretrovirals Amodiaquine + artemisinin

22


23


Correct information and its proper communication can reduce (preventable) ADRs

27th Annual Meeting of Representatives of the National Centres participating in the WHO Programme for International Drug Monitoring Dublin, Ireland, 4 - 6 October 2004 The summary of product characteristics (SPC) could be an

effective tool in preventing ADRs. Accurate and recent information should be provided in the SPCs. The SPC should be appropriately worded and presented to help health professionals get the summary quickly and with the least effort. Doctors should be advised to read all package inserts and labels.

24


Two different regulatory approaches to medicines information: Australian example

Therapeutic Goods Regulations 1990 (compliant 1 October 2004) Schedules 12 and 13 for prescription and pharmacy only products Content based regulation whereby a list of required information is

prescribed Therapeutic Goods Roder 69A for non-prescription and

complementary products Performance based regulation whereby regulation identifies the

tasks that consumers ought to be able to carry out using the information

25


Conclusions on iformation

Medicine = tablet + information Good quality drug information including PILs is a shared

responsibility of industry and regulators Regulators with limited resources could do more for public

health by trusting scientific assessments by well resourced DRAs and concentrating more on ensuring the accuracy of drug information in national settings

Not only accuracy of information but also its proper communication is important

26


…and realities

In many countries do not have enough resources to check information or approve SPCs and PIL

In some countries prescription only medicines do not have PIL (OTC medicines have) …but can be obtained without any prescription

Most of the World population has only one prescription for all medicines – banknote. Can this give them also the information they need and understand?

27


Realities…

28


Structure of the dossier

Would it be harmonised a lot of resources would be saved Industries would have one dossier structure for different

submissions Regulators could communicate better

29


30


31


32


33


34


35


36


37


38


General Principles of Medicines Regulation Dr Lembit Rägo Coordinator Quality Assurance and Safety:...

Documents

Transcript of General Principles of Medicines Regulation Dr Lembit Rägo Coordinator Quality Assurance and Safety:...